MCID: ANG020
MIFTS: 59

Angiosarcoma

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angiosarcoma

MalaCards integrated aliases for Angiosarcoma:

Name: Angiosarcoma 12 77 60 38 56 6 15 41 17
Hemangiosarcoma 12 45 74

Characteristics:

Orphanet epidemiological data:

60
angiosarcoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0001816
KEGG 38 H01666
MeSH 45 D006394
NCIt 51 C3088 C9275
SNOMED-CT 69 33176006 39000009
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0018923
Orphanet 60 ORPHA263413

Summaries for Angiosarcoma

Disease Ontology : 12 A vascular cancer that derives from the cells that line the walls of blood vessels or lymphatic vessels.

MalaCards based summary : Angiosarcoma, also known as hemangiosarcoma, is related to liver angiosarcoma and lymphangiosarcoma. An important gene associated with Angiosarcoma is PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ethiodized oil and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and heart, and related phenotypes are Decreased cell migration and Increased senescence-associated beta-galactosidase protein expression after pRB stimulation

Wikipedia : 77 Angiosarcoma is a cancer of the cells that line the walls of blood vessels or lymphatic vessels. The... more...

Related Diseases for Angiosarcoma

Diseases related to Angiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 429)
# Related Disease Score Top Affiliating Genes
1 liver angiosarcoma 34.2 KRAS VIM VWF
2 lymphangiosarcoma 32.7 FLT4 MYC PROX1 VEGFA VWF
3 epithelioid hemangioendothelioma 32.6 FLT1 KDR VEGFA
4 intravascular papillary endothelial hyperplasia 32.5 VEGFA VIM
5 hemangioendothelioma 32.0 FLI1 FLT4 KDR PECAM1
6 kaposi sarcoma 30.5 KDR MYC VEGFA
7 sarcoma 30.2 FLI1 KDR KIT KRAS VIM
8 pyogenic granuloma 29.9 TEK VEGFA
9 malignant peripheral nerve sheath tumor 29.9 KIT MUC1 VIM
10 malignant epithelioid hemangioendothelioma 29.9 FLT4 KDR MYC
11 adenoid squamous cell carcinoma 29.9 KRT8 VIM
12 benign breast phyllodes tumor 29.8 KIT VIM
13 adenocarcinoma 29.7 KDR KIT KRAS MUC1 MYC VEGFA
14 secretory meningioma 29.7 MUC1 VIM
15 gastrointestinal stromal tumor 29.7 KIT KRAS VEGFA VIM
16 thyroid cancer 29.6 KDR KIT KRAS MYC VEGFA
17 carcinosarcoma 29.6 KIT KRAS MUC1 VIM
18 arteries, anomalies of 29.6 FLT1 VEGFA VWF
19 cavernous hemangioma 29.6 KDR KIT MUC1 PECAM1 VIM
20 lymphangioma 29.5 FLT4 KDR PROX1 VEGFA VIM
21 hemangioma 29.5 FLT1 FLT4 KDR KRAS PECAM1 PROX1
22 perivascular epithelioid cell tumor 29.4 KIT MUC1 VIM
23 capillary hemangioma 29.1 FLT1 KDR PECAM1 TEK VEGFA
24 epithelioid sarcoma 29.1 KRT8 MUC1 VIM
25 lung cancer 29.0 FLT1 FLT4 KDR KIT KRAS MYC
26 merkel cell carcinoma 29.0 KIT KRT8 MUC1
27 sarcoma, synovial 28.7 KIT KRT8 MUC1 VIM
28 ewing sarcoma 28.4 FLI1 FLT1 KDR KIT MYC VEGFA
29 breast cancer 28.4 FLT1 FLT4 KDR KIT KRAS KRT8
30 renal cell carcinoma, nonpapillary 28.2 FLT1 FLT4 KDR KIT KRT8 MUC1
31 gastric adenocarcinoma 28.2 KDR KIT KRAS KRT8 MUC1 MYC
32 breast angiosarcoma 12.5
33 spleen angiosarcoma 12.4
34 skin angiosarcoma 12.4
35 thyroid angiosarcoma 12.4
36 angiosarcoma of the scalp 12.4
37 pediatric angiosarcoma 12.4
38 prostate angiosarcoma 12.4
39 aorta angiosarcoma 12.3
40 gallbladder angiosarcoma 12.3
41 mediastinum angiosarcoma 12.2
42 ovarian angiosarcoma 12.2
43 superior vena cava angiosarcoma 12.2
44 radiation induced angiosarcoma of the breast 12.2
45 central nervous system angiosarcoma 12.2
46 conventional angiosarcoma 12.1
47 pseudoangiomatous stromal hyperplasia 11.0
48 bone angioendothelial sarcoma 11.0
49 hemifacial spasm 10.4 FLT4 VEGFA
50 lymphedema 10.4

Graphical network of the top 20 diseases related to Angiosarcoma:



Diseases related to Angiosarcoma

Symptoms & Phenotypes for Angiosarcoma

GenomeRNAi Phenotypes related to Angiosarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 FLT1 KDR KRAS MUC1 VIM
2 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.8 FLT1 KIT TEK

MGI Mouse Phenotypes related to Angiosarcoma:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 FLI1 FLT1 FLT4 KDR KIT KRAS
2 hematopoietic system MP:0005397 10.32 FLI1 FLT1 KDR KIT KRAS KRT8
3 homeostasis/metabolism MP:0005376 10.31 FLT1 FLT4 KDR KIT KRAS KRT8
4 cellular MP:0005384 10.3 FLI1 FLT1 KDR KIT KRAS MYC
5 immune system MP:0005387 10.29 FLI1 FLT1 FLT4 KDR KIT KRAS
6 embryo MP:0005380 10.28 FLI1 FLT1 FLT4 KDR KIT KRAS
7 growth/size/body region MP:0005378 10.26 FLI1 FLT1 FLT4 KDR KIT KRAS
8 mortality/aging MP:0010768 10.25 FLI1 FLT1 FLT4 KDR KIT KRAS
9 digestive/alimentary MP:0005381 10.2 FLT4 KIT KRAS KRT8 MYC PECAM1
10 muscle MP:0005369 10.18 FLI1 FLT1 FLT4 KDR KIT KRAS
11 liver/biliary system MP:0005370 10.16 FLI1 FLT4 KDR KIT KRAS KRT8
12 nervous system MP:0003631 10.11 FLI1 FLT1 KDR KIT KRAS MYC
13 normal MP:0002873 9.91 FLT1 FLT4 KDR KIT KRAS MYC
14 no phenotypic analysis MP:0003012 9.87 FLT4 KDR KIT KRAS MYC VEGFA
15 reproductive system MP:0005389 9.76 FLT1 FLT4 KIT KRAS KRT8 MYC
16 respiratory system MP:0005388 9.5 KDR KIT KRAS PECAM1 PROX1 VEGFA
17 vision/eye MP:0005391 9.23 FLT1 KDR KIT KRAS PROX1 TEK

Drugs & Therapeutics for Angiosarcoma

Drugs for Angiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
8
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
9
Carboplatin Approved Phase 3,Phase 2 41575-94-4 38904 10339178 498142
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14
Histamine Approved, Investigational Phase 3 51-45-6 774
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
20 Alkylating Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Etoposide phosphate Phase 3,Phase 2
25 Immunologic Factors Phase 3,Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
27 Antirheumatic Agents Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 3,Phase 2
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 3,Phase 2,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1
33 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
34 Serotonin Agents Phase 3
35 Serotonin Antagonists Phase 3
36 Histamine H1 Antagonists Phase 3
37 Anti-Allergic Agents Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Gastrointestinal Agents Phase 3
40 Histamine Antagonists Phase 3
41 Antipruritics Phase 3
42 Dermatologic Agents Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Everolimus Approved Phase 2 159351-69-6 6442177 70789204

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
12 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
13 A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA Recruiting NCT02979899 Phase 3 Votrient
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Unknown status NCT01303497 Phase 2 Paclitaxel;Bevacizumab
17 Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery Unknown status NCT00874874 Phase 2 sorafenib tosylate
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
20 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Completed NCT01623869 Phase 2
21 Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery Completed NCT00217607 Phase 2 paclitaxel
22 Bevacizumab in Treating Patients With Angiosarcoma Completed NCT00288015 Phase 2
23 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
24 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
25 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
26 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
27 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
28 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
29 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
30 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
31 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
32 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
33 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
34 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
36 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
37 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
38 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
39 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
40 Paclitaxel-Avelumab for Angiosarcoma Recruiting NCT03512834 Phase 2 Avelumab;Paclitaxel
41 Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Recruiting NCT03331250 Phase 2 Eribulin
42 Evaluation of Votrient in Angiosarcoma Recruiting NCT02212015 Phase 2 Pazopanib + Paclitaxel
43 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Recruiting NCT01462630 Phase 2 pazopanib hydrochloride
44 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Recruiting NCT02048722 Phase 2 regorafenib
45 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
46 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
47 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
48 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab
49 A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Active, not recruiting NCT01140737 Phase 2 Axitinib
50 A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Active, not recruiting NCT01975519 Phase 1, Phase 2 TRC105 and Pazopanib

Search NIH Clinical Center for Angiosarcoma

Cochrane evidence based reviews: hemangiosarcoma

Genetic Tests for Angiosarcoma

Anatomical Context for Angiosarcoma

MalaCards organs/tissues related to Angiosarcoma:

42
Breast, Liver, Heart, Bone, Spleen, Lung, Thyroid

Publications for Angiosarcoma

Articles related to Angiosarcoma:

(show top 50) (show all 3234)
# Title Authors Year
1
Popliteal Angiosarcoma after Bypass with Autologous Saphenous Vein. ( 30217704 )
2019
2
Primary perirenal angiosarcoma: A rare presentation of a perirenal mass. ( 30305861 )
2019
3
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). ( 30357394 )
2019
4
Primary and Secondary Breast Angiosarcoma: FDG PET/CT Series. ( 30371579 )
2019
5
Hepatic Angiosarcoma: A Multi-institutional, International Experience with 44 Cases. ( 30456677 )
2019
6
Epithelioid angiosarcoma arising from a frontoparietal arteriovenous malformation. ( 30520560 )
2019
7
Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability. ( 30611463 )
2019
8
Malignant peripheral nerve sheath tumor (MPNST) arising from angiosarcoma: a rare case report. ( 30617438 )
2019
9
Primary Common Iliac Artery Angiosarcoma With Multiple Bone Metastases Revealed by Dual-Time Point FDG PET/CT Imaging. ( 30624266 )
2019
10
Splenic Angiosarcoma Diagnosed on Bone Marrow Biopsy: Case Report and Literature Review. ( 30627296 )
2019
11
Surgical therapy of primary hepatic angiosarcoma. ( 30630447 )
2019
12
The role of differential diagnosis in intravascular papillary endothelial hyperplasia of the sinonasal cavity mimicking angiosarcoma: A case report. ( 30655892 )
2019
13
Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study. ( 30676608 )
2019
14
CT and MRI studies of hepatic angiosarcoma. ( 30686504 )
2019
15
A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. ( 30703514 )
2019
16
Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment. ( 30704938 )
2019
17
Clinical Outcomes and Prognostic Features of Angiosarcoma: Significance of Prior Radiation Therapy. ( 30718086 )
2019
18
ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. ( 30719217 )
2019
19
Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study. ( 30723294 )
2019
20
Early appearance of post-radiation angiosarcoma of the breast. ( 30727036 )
2019
21
Marrow involvement by metastatic spindle cell angiosarcoma. ( 30733205 )
2019
22
Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy - A Systematic Review. ( 30738715 )
2019
23
Clinical and imaging manifestations of primary cardiac angiosarcoma. ( 30764784 )
2019
24
Regulation of PD-L1 expression by aPKCλ in cutaneous angiosarcoma. ( 30801864 )
2019
25
Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma. ( 30820717 )
2019
26
Corrigendum to 'Primary thyroid angiosarcoma: A systematic review' [Oral Oncol. 82 (2018) 48-52]. ( 30824286 )
2019
27
SIRT1 Expression Is Associated With Cell Proliferation in Angiosarcoma. ( 30842143 )
2019
28
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma. ( 30850173 )
2019
29
Primary pulmonary angiosarcoma: case reports and review of the literature. ( 30857394 )
2019
30
A case of aggressive recurrent intracranial subdural hematoma associated with angiosarcoma originating from the skull. ( 30862578 )
2019
31
Terminal Bleeding in Angiosarcoma. ( 30864873 )
2019
32
Anti-Amphiphysin-associated limbic encephalitis in a 72-year-old patient with aortic angiosarcoma. ( 30872337 )
2019
33
Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC). ( 30877870 )
2019
34
A case of recurrent angiosarcoma with isolated bone marrow metastasis presented as acute disseminated intravascular coagulation. ( 30887676 )
2019
35
Primary Renal Angiosarcoma Mimicking Renal Cell Carcinoma: A Case Report. ( 30891382 )
2019
36
Cutaneous angiosarcoma: a rare complication post-male breast cancer radiotherapy. ( 28643893 )
2019
37
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions. ( 30601866 )
2019
38
Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma. ( 30670791 )
2019
39
Tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro. ( 30767429 )
2019
40
Prevalence, distribution, and clinical characteristics of hemangiosarcoma-associated skeletal muscle metastases in 61 dogs: A whole body computed tomographic study. ( 30793807 )
2019
41
Primary angiosarcoma of the femur in a patient with Takayasu arteritis. ( 29892593 )
2018
42
Mediastinal angiosarcoma presenting as diffuse alveolar hemorrhage. ( 29719795 )
2018
43
A Patient Presenting with Cardiac Tamponade and the Challenges of Finding Its Cause: A Cardiac Angiosarcoma. ( 29682355 )
2018
44
Impact of specialist management on survival from radiation-associated angiosarcoma of the breast. ( 29405251 )
2018
45
Treatment of cutaneous angiosarcoma of the scalp and face in Chinese patients: local experience at a regional hospital in Hong Kong. ( 29326400 )
2018
46
Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. ( 29863582 )
2018
47
Jejunal angiosarcoma: a rare cause of obscure gastrointestinal bleeding with successful resection after enteroscopic localization. ( 29882282 )
2018
48
Primary Angiosarcoma of the Breast after Bilateral Breast Reduction. ( 29977639 )
2018
49
Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: A care-compliant case report and literature review. ( 29384853 )
2018
50
PD-L1-Expressing Radiation-Associated Angiosarcoma after Primary Breast Cancer. ( 29928212 )
2018

Variations for Angiosarcoma

ClinVar genetic disease variations for Angiosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_004985.4(KRAS): c.57G> C (p.Leu19Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs121913538 GRCh38 Chromosome 12, 25245328: 25245328
2 KRAS NM_004985.4(KRAS): c.57G> C (p.Leu19Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs121913538 GRCh37 Chromosome 12, 25398262: 25398262
3 MED12 NM_005120.2(MED12): c.130G> A (p.Gly44Ser) single nucleotide variant other rs199469669 GRCh37 Chromosome X, 70339253: 70339253
4 MED12 NM_005120.2(MED12): c.130G> A (p.Gly44Ser) single nucleotide variant other rs199469669 GRCh38 Chromosome X, 71119403: 71119403
5 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh37 Chromosome 12, 25398262: 25398262
6 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh38 Chromosome 12, 25245328: 25245328

Expression for Angiosarcoma

Search GEO for disease gene expression data for Angiosarcoma.

Pathways for Angiosarcoma

Pathways related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 FLT1 FLT4 KDR KIT KRAS MUC1
2
Show member pathways
13.64 FLT1 FLT4 KDR KIT KRAS MYC
3
Show member pathways
13.47 FLT1 FLT4 KDR KIT KRAS MYC
4
Show member pathways
13.42 KDR KIT KRAS KRT8 TEK VEGFA
5
Show member pathways
13.27 KIT KRAS MUC1 MYC TEK VEGFA
6
Show member pathways
13.25 FLT1 FLT4 KDR KIT KRAS TEK
7
Show member pathways
13.23 FLT1 FLT4 KDR KIT KRAS TEK
8
Show member pathways
13.18 FLT1 FLT4 KDR KIT KRAS TEK
9
Show member pathways
12.99 FLT1 FLT4 KDR KIT KRAS
10
Show member pathways
12.98 FLT1 FLT4 KDR KIT KRAS
11
Show member pathways
12.92 FLT1 FLT4 KDR KIT TEK
12
Show member pathways
12.84 FLT1 FLT4 KDR KRAS VEGFA VWF
13 12.77 FLT4 KIT KRAS MYC VEGFA
14
Show member pathways
12.64 FLT1 FLT4 KDR KIT KRAS MYC
15
Show member pathways
12.62 FLT1 FLT4 KDR KIT KRAS TEK
16 12.53 FLT1 FLT4 KDR KIT KRAS MYC
17 12.46 KRAS MYC VEGFA VIM
18
Show member pathways
12.44 FLT1 FLT4 KDR KRAS
19
Show member pathways
12.38 FLT1 FLT4 KDR KRAS
20
Show member pathways
12.37 FLT1 FLT4 KDR KRAS VEGFA
21
Show member pathways
12.34 FLT1 FLT4 KDR VEGFA
22
Show member pathways
12.32 FLT1 FLT4 KDR KIT KRAS TEK
23 12.25 KDR KRAS MYC VEGFA
24
Show member pathways
12.2 FLT1 FLT4 KDR KIT KRAS MYC
25
Show member pathways
12.19 FLT1 KDR KRAS VEGFA
26
Show member pathways
12.12 FLT1 FLT4 KDR KRAS MYC TEK
27 12.06 FLT1 FLT4 KDR KIT TEK
28
Show member pathways
12.03 FLT1 FLT4 KDR KRAS MYC
29 12.02 KDR PECAM1 VEGFA
30 12 KDR MYC PROX1 VEGFA VIM
31 11.95 FLT1 FLT4 KDR KRAS MYC TEK
32 11.94 MUC1 MYC VEGFA VIM
33
Show member pathways
11.93 FLT1 KDR VEGFA
34 11.86 FLT1 TEK VEGFA
35
Show member pathways
11.83 FLT1 FLT4 KDR VEGFA
36
Show member pathways
11.82 KIT MYC VEGFA
37 11.81 FLT1 TEK VEGFA
38
Show member pathways
11.72 FLT1 FLT4 KDR KIT
39 11.69 KRAS MYC VEGFA
40
Show member pathways
11.69 FLT1 FLT4 KDR KIT KRAS
41 11.64 KIT KRAS MYC
42 11.49 KRAS MYC VEGFA
43 11.32 FLT1 KDR VEGFA
44 11.12 FLT1 FLT4 KDR PECAM1 PROX1 TEK
45 11.09 FLT1 KDR TEK VEGFA
46 11.07 FLT1 FLT4 KDR VEGFA
47 11.07 FLT1 FLT4 KDR KRAS MYC VEGFA
48 10.96 FLT1 FLT4 KDR KIT TEK VIM

GO Terms for Angiosarcoma

Cellular components related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 FLT1 FLT4 KDR KIT MUC1 TEK
2 cytoplasm GO:0005737 9.73 FLT1 FLT4 KDR KIT KRAS KRT8
3 focal adhesion GO:0005925 9.56 FLT1 KRAS TEK VIM
4 membrane raft GO:0045121 9.46 KDR KRAS PECAM1 TEK
5 receptor complex GO:0043235 9.02 FLT1 FLT4 KDR KIT TEK

Biological processes related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 FLT1 FLT4 KDR KIT TEK
2 positive regulation of protein phosphorylation GO:0001934 9.95 FLT4 KDR KRAS TEK VEGFA
3 positive regulation of cell migration GO:0030335 9.93 FLT1 KDR KIT VEGFA
4 MAPK cascade GO:0000165 9.93 KIT KRAS MYC TEK
5 positive regulation of angiogenesis GO:0045766 9.91 FLT1 KDR TEK VEGFA
6 peptidyl-tyrosine phosphorylation GO:0018108 9.91 FLT1 FLT4 KDR KIT TEK
7 cytokine-mediated signaling pathway GO:0019221 9.91 KIT KRAS MUC1 MYC VEGFA VIM
8 protein autophosphorylation GO:0046777 9.89 FLT1 FLT4 KDR KIT TEK
9 cell differentiation GO:0030154 9.88 FLI1 FLT1 KDR VEGFA
10 negative regulation of apoptotic process GO:0043066 9.88 FLT4 KDR MYC TEK VEGFA
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.86 FLT1 KDR KIT TEK
12 platelet degranulation GO:0002576 9.85 PECAM1 VEGFA VWF
13 angiogenesis GO:0001525 9.85 FLT1 FLT4 KDR PECAM1 TEK VEGFA
14 positive regulation of MAP kinase activity GO:0043406 9.84 FLT1 KIT KRAS VEGFA
15 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.83 FLT1 FLT4 KDR VEGFA
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 KIT PECAM1 VEGFA
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.77 FLT1 KIT TEK
18 sprouting angiogenesis GO:0002040 9.77 FLT4 TEK VEGFA
19 positive regulation of MAPK cascade GO:0043410 9.76 FLT1 FLT4 KDR KIT
20 positive regulation of cell proliferation GO:0008284 9.76 FLT1 FLT4 KDR KIT KRAS MYC
21 positive regulation of focal adhesion assembly GO:0051894 9.75 KDR TEK VEGFA
22 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.72 FLT1 FLT4 KDR KIT TEK
23 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.71 FLT1 FLT4 KDR VEGFA
24 cell migration involved in sprouting angiogenesis GO:0002042 9.68 KDR VEGFA
25 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.68 FLT1 VEGFA
26 embryonic hemopoiesis GO:0035162 9.67 KDR KIT
27 megakaryocyte development GO:0035855 9.67 FLI1 KIT
28 positive regulation of phospholipase C activity GO:0010863 9.66 FLT1 KIT
29 lymph vessel development GO:0001945 9.65 FLT4 PROX1
30 lymphangiogenesis GO:0001946 9.65 FLT4 PROX1
31 positive regulation of positive chemotaxis GO:0050927 9.65 KDR VEGFA
32 positive regulation of endothelial cell proliferation GO:0001938 9.65 FLT4 KDR PROX1 TEK VEGFA
33 positive regulation of protein kinase C signaling GO:0090037 9.64 FLT4 VEGFA
34 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 KDR VEGFA
35 ovarian follicle development GO:0001541 9.61 KIT VEGFA
36 vascular endothelial growth factor signaling pathway GO:0038084 9.26 FLT1 FLT4 KDR VEGFA
37 positive regulation of endothelial cell migration GO:0010595 9.02 FLT4 KDR PROX1 TEK VEGFA
38 phosphorylation GO:0016310 10.06 FLT1 FLT4 KDR KIT TEK
39 protein phosphorylation GO:0006468 10.06 FLT1 FLT4 KDR KIT TEK
40 positive regulation of gene expression GO:0010628 10.02 KIT KRAS MYC VEGFA VIM

Molecular functions related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.8 FLT1 FLT4 KDR KIT TEK
2 protein kinase activity GO:0004672 9.77 FLT1 FLT4 KDR KIT TEK
3 protein tyrosine kinase activity GO:0004713 9.65 FLT1 FLT4 KDR KIT TEK
4 growth factor binding GO:0019838 9.46 FLT1 FLT4 KDR TEK
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.13 FLT1 FLT4 KDR
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FLT1 FLT4 KDR KIT TEK
7 protein binding GO:0005515 10.2 FLI1 FLT1 FLT4 KDR KIT KRAS

Sources for Angiosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....